Jane Street
TRDA icon

Jane Street’s Entrada Therapeutics TRDA Stock Holding History

Jane Street’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,213
Closed -$470K – 13145
2026
Q1 		$470K Sell
37,213
-48,449
-57% -$555K ﹤0.01% 8202
2025
Q4 		$881K Sell
85,662
-161,854
-65% -$1.36M ﹤0.01% 6390
2025
Q3 		$1.44M Buy
247,516
+196,358
+384% +$1.15M ﹤0.01% 5555
2025
Q2 		$344K Buy
+51,158
New +$412K ﹤0.01% 7613
2024
Q4 		– Sell
-15,514
Closed -$248K – 10599
2024
Q3 		$248K Sell
15,514
-11,240
-42% -$177K ﹤0.01% 8334
2024
Q2 		$381K Buy
+26,754
New +$380K ﹤0.01% 7437
2023
Q2 		– Sell
-73,898
Closed -$1.07M – 9568
2023
Q1 		$1.07M Buy
73,898
+59,374
+409% +$793K ﹤0.01% 4868
2022
Q4 		$196K Buy
+14,524
New +$255K ﹤0.01% 7678

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Jane Street's TRDA Position: Q2 2026 in Review

Jane Street sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 37,213 shares — an estimated $470K sold.

Jane Street first reported a position in TRDA in Q4 2022 and held it in 8 quarters. The position peaked at $1.44M in Q3 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Jane Street reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 37,213 Entrada Therapeutics shares in Q2 2026, an estimated $470K.
  • Jane Street first reported a position in Entrada Therapeutics in Q4 2022 and held it in 8 quarters.
  • Jane Street's Entrada Therapeutics position peaked at $1.44M in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.